Sage Journals: Discover world-class research

Abstract

Prostate cancer (PCa) is the second most commonly diagnosed and sixth leading cause of cancer death in American men and one for which no curative therapy exists after metastasis. To meet this need for novel therapies, our laboratory has previously generated conditionally replicating adenovirus (CRAd) vectors expressing the sodium iodide symporter (hNIS). This virus transduced PCa cells and induced functional NIS expression, allowing for noninvasive tumor imaging and combination therapy with radioiodide, referred to as radiovirotherapy. We have now generated two new modified vectors to further improve efficacy. Ad5/3PB-ADP-hNIS and Ad5/3PB-hNIS include a hybrid Ad5/3 fiber knob to improve transduction efficiency, and express NIS from the endogenous major late promoter to restrict NIS expression to target cells. Additionally, Ad5/3PB-ADP-hNIS includes the adenovirus death protein (ADP), which hastens the release of viral particles after assembly. These two vectors specifically induce radioisotope uptake, cytopathic effect, and viral replication in androgen receptor–expressing PCa cell lines with Ad5/3PB-ADP-hNIS showing earlier ¹³¹I uptake and cytolysis at low multiplicity of infection. SPECT-CT imaging of xenograft tumors infected with Ad5/3PB-hNIS showed steady uptake, whereas infection with Ad5/3PB-ADP-hNIS led to increasing uptake, indicating viral spread. Radiovirotherapy of xenograft LNCaP tumors with Ad5/3PB-ADP-hNIS showed the most significant survival extension versus control tumors (p=0.001), but the benefit of radiovirotherapy was not statistically significant compared with virotherapy alone in this model. These results show the potential of Ad5/3PB-ADP-hNIS as a vector for treatment of prostate cancer.

Get full access to this article

View all access options for this article.

References

Andriani

, Nan

, Yu

et al. 2001. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J. Natl. Cancer Inst., 93:1314–1324.

Barton

K.N.

, Paielli

, Zhang

et al. 2006. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther., 13:347–356.

Barton

K.N.

, Stricker

, Brown

S.L.

et al. 2008. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther., 16:1761–1769.

Cho

J.-Y.

, Xing

, Liu

et al. 2000. Expression and activity of human Na⁺/I⁻ symporter in human glioma cells by adenovirus mediated gene therapy. Gene Ther., 7:740–749.

Crnalic

, Hörnberg

, Wikström

et al. 2010. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr. Relat. Cancer, 17:885–895.

Dash

, Dmitriev

, Su

Z.Z.

et al. 2010. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Ther., 17:447–456.

Davis

B.J.

2011(ongoing))Gene therapy and radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy. http://clinicaltrials.gov/ct2/show/NCT00788307. 2012 June 22.

Davydova

, Le

L.P.

, Gavrikova

et al. 2004. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res., 64:4319–4327.

Davydova

, Gavrikova

, Brown

E.J.

et al. 2010. In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci., 101:474–481.

10.

Dingli

, Peng

K.-W.

, Harvey

M.E.

et al. 2004. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood, 103:1641–1646.

11.

Doronin

, Toth

, Kuppuswamy

et al. 2003. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology, 305:378–387.

12.

Dwyer

R.M.

, Bergert

E.R.

, O'Connor

M.K.

et al. 2005. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin. Cancer Res., 11:1483–1489.

13.

Edwards

, Krishna

N.S.

, Grigor

K.M.

, Bartlett

J.M.S.

2003. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer, 89:552–556.

14.

Galanis

2011(ongoing))Recombinant measles virus vaccine therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer. http://clinicaltrials.gov/ct2/show/NCT00408590. 2012 June 22.

15.

Gregory

C.W.

, Johnson

R.T.

, Mohler

J.L.

et al. 2001. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res., 61:2892–2898.

16.

Hanahan

, Weinberg

R.A.

2011. Hallmarks of cancer: the next generation. Cell, 144:646–674.

17.

Holzbeierlein

, Lal

, Latulippe

et al. 2004. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol., 164:217–227.

18.

Hugosson

, Stranne

, Carlsson

S.V.

2011. Radical retropubic prostatectomy: a review of outcomes and side-effects. Acta Oncol., 50:92–97.

19.

Jemal

, Bray

, Center

M.M.

et al. 2011. Global cancer statistics. CA Cancer J. Clin., 61:69–90.

20.

Kakinuma

, Bergert

E.R.

, Spitzweg

et al. 2003. Probasin promoter (ARR2PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res., 63:7840–7844.

21.

Kuster

, Koschel

, Rohwer

et al. 2010. Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1[alpha] Cancer Gene Ther., 17:141–146.

22.

Linja

M.J.

, Savinainen

K.J.

, Saramäki

O.R.

et al. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 61:3550–3555.

23.

Luster

, Clarke

, Dietlein

et al. 2008. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging, 35:1941–1959.

24.

Lutz

, Kedinger

1996. Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. J. Virol., 70:1396–1405.

25.

Mandell

R.B.

, Mandell

L.Z.

, Link

C.J.

1999. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res., 59:661–668.

26.

Mottet

, Bellmunt

, Bolla

et al. 2011. EAU Guidelines on Prostate Cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol., 59:572–583.

27.

Murakami

, Ugai

, Belousova

et al. 2010. Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells. Prostate, 70:362–376.

28.

Ono

H.A.

, Le

L.P.

, Davydova

J.G.

et al. 2005. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res., 65:10154–10158.

29.

C.F.

, Li

, Song

Y.J.

et al. 2004. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate. Br. J. Cancer, 91:2086–2093.

30.

Rauen

K.A.

, Sudilovsky

, Le

J.L.

et al. 2002. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma. Cancer Res., 62:3812–3818.

31.

Scosyrev

, Messing

E.M.

, Mohile

et al. 2011. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer, 118:3062–3070.

32.

Spitzweg

, Dietz

A.B.

, O'Connor

M.K.

et al. 2001. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther., 8:1524–1531.

33.

Tannock

I.F.

, De Wit

, Berry

W.R.

et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 351:1502–1512.

34.

Tollefson

A.E.

, Ryerse

J.S.

, Scaria

et al. 1996. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with ADP mutants. Virology, 220:152–162.

35.

Tribouley

, Lutz

, Staub

, Kedinger

1994. The product of the adenovirus intermediate gene IVa2 is a transcriptional activator of the major late promoter. J. Virol., 68:4450–4457.

36.

Trojan

, Schaaf

, Steidler

et al. 2005. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res., 25:183–191.

37.

Trujillo

, Oneal

, Davydova

et al. 2009. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res., 11:R53.

38.

Trujillo

M.A.

, Oneal

M.J.

, McDonough

et al. 2010. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther., 17:1325–1332.

39.

Waehler

, Russell

S.J.

, Curiel

D.T.

2007. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet., 8:573–587.

40.

Wang

, Li

Z.-Y.

, Liu

et al. 2011. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med., 17:96–104.

41.

Yamamoto

, Davydova

, Wang

et al. 2003. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology, 125:1203–1218.

42.

Zhang

, Thomas

T.Z.

, Kasper

, Matusik

R.J.

2000. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology, 141:4698–4710.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.05 MB

0.04 MB

Characterization of Infectivity-Enhanced Conditionally Replicating Adenovectors for Prostate Cancer Radiovirotherapy

Abstract

Get full access to this article

References

Supplementary Material